Madrigal Pharmaceuticals, Inc. (MDGL) News

Madrigal Pharmaceuticals, Inc. (MDGL): $320.81

3.72 (+1.17%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Filter MDGL News Items

MDGL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MDGL News Highlights

  • For MDGL, its 30 day story count is now at 6.
  • Over the past 15 days, the trend for MDGL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about MDGL are BIO, DEC and DRUG.

Latest MDGL News From Around the Web

Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan. The equity awards were approved in

Yahoo | December 22, 2023

Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL)

In a recent transaction on December 15, 2023, Robert Waltermire, Senior Vice President and Chief of Pharmaceutical Development at Madrigal Pharmaceuticals Inc, sold 4,000 shares of the company's stock.

Yahoo | December 19, 2023

11 Stocks Insiders and Billionaires Are Crazy About

In this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […]

Yahoo | December 19, 2023

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit

Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) is possibly approaching a major achievement in its business, so we would...

Yahoo | December 17, 2023

Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has recently witnessed a significant insider sell that has caught the attention of investors and market analysts.

Yahoo | December 16, 2023

These 2 Stocks Could Be About to Soar: Are They Buys?

Shares of relatively small biotech companies often soar when they get positive news from regulators, and that's exactly what Madrigal Pharmaceuticals (NASDAQ: MDGL) and Bluebird Bio (NASDAQ: BLUE) are awaiting. Madrigal Pharmaceuticals is a clinical-stage biotech that may have made a significant breakthrough. Madrigal submitted an application for resmetirom, its potential NASH therapy, to the Food and Drug Administration (FDA) for review in July.

Yahoo | December 7, 2023

11 Best Upside Stocks To Buy Right Now

In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […]

Yahoo | November 27, 2023

Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors

OrbiMed Advisors is part of a partnership interested in acquiring all of Kinnate Biopharma. Baker Brothers increased an investment in Madrigal Pharmaceuticals.

Yahoo | November 24, 2023

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and

Yahoo | November 21, 2023

Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

Yahoo | November 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!